Friday, July 10, 2026

pharma · Early Childhood Caries · Acute Myeloid Leukemia

University of Hong

University of Hong is a pharma organization headquartered in CN. Primary therapeutic focus areas include Early Childhood Caries, Acute Myeloid Leukemia, Influenza Virus Infection, Smoking Cessation, Influenza. NovaPharma

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
42
Drugs
71
Patents
0
Clinical program

25% AgNO3 solution followed by 5% NaF

Phase 3 · small molecule · Early Childhood Caries

25% AgNO3 solution followed by 5% NaF for Early Childhood Caries is a Phase 3 program (small_molecule) at The University of Hong Kong with 1 ClinicalTrials.gov record(s).

← All The University of Hong Kong projects Phase 3 small molecule completed

Internal code UW 17-176

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
The University of Hong Kong
Phase
Phase 3
Modality
small_molecule
Indication
Early Childhood Caries
Status
completed
Trials
1